Important note: Information in this article was accurate in May 2008. The state of the art may have changed since the publication date.
Raltegravir approved in Scotland
HIV Treat Bull - 2008 May-June;9(5/6):27
On 12 May the Scottish Medicines Consortium (SMC) announced that raltegravir (Isentress) has been accepted for restricted use within NHS Scotland in combination with other antiretroviral medicinal products agents for the treatment of HIV-1 in treatment-experienced adult patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy.[1]
It is restricted to patients with triple class resistant HIV-1 infection. Raltegravir was approved in Europe on 23 January.[2]
References
2008-05-10
IB080905-25
©2008. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.